Table 1 Associations between PODXL expression and EGFR expression, BRAF, KRAS mutations and MSI status in colorectal cancer

N (%)

268 (50.0)

186 (34.7)

10 (1.9)

71 (13.2)

1 (0.2)

137 (50.7)

67 (24.8)

31 (11.5)

25 (9.3)

0 (0.0)

197 (56.3)

65 (18.6)

29 (8.3)

22 (6.3)

3 (0.9)

EGFR

 Low

225 (87.5)

141 (77.9)

7 (70.0)

34 (48.6)

0 (0.0)

106 (80.3)

55 (84.6)

22 (73.3)

12 (50.0)

0 (0.0)

171 (89.5)

55 (85.9)

21 (72.4)

10 (47.6)

0 (0.0)

 High

32 (12.5)

40 (22.1)

3 (30.0)

36 (51.4)

1 (100.0)

26 (19.7)

10 (15.4)

8 (26.7)

12 (50.0)

0 (0.0)

20 (10.5)

9 (14.1)

8 (27.6)

11 (52.4)

3 (100.0)

 Missing

11

5

1

5

2

1

1

6

1

1

BRAF status

 Wt

227 (90.8)

153 (85.5)

4 (40.0)

45 (70.3)

0 (0.0)

N/A

N/A

N/A

N/A

N/A

123 (89.8)

33 (78.6)

12 (60.0)

13 (81.3)

0 (0.0)

 Mutated

23 (9.2)

26 (14.5)

6 (60.0)

19 (29.7)

1 (100.0)

N/A

N/A

N/A

N/A

N/A

14 (10.2)

9 (21.4)

8 (40.0)

3 (18.7)

2 (100.0)

 Missing

18

7

7

60

23

9

6

1

KRAS status

 Wt

153 (61.0)

118 (65.9)

9 (90.0)

41 (64.1)

1 (100.0)

N/A

N/A

N/A

N/A

N/A

75 (58.1)

29 (70.7)

17 (85.0)

8 (57.1)

2 (100.0)

 Mutated

98 (39.0)

61 (34.1)

1 (10.0)

23 (35.9)

0 (0.0)

N/A

N/A

N/A

N/A

N/A

54 (41.9)

12 (29.3)

3 (15.0)

6 (42.9)

0 (0.0)

 Missing

17

7

7

68

24

9

8

1

MSI status

 MSS

227 (88.7)

146 (84.9)

0 (0.0)

52 (80.0)

1 (100.0)

N/A

N/A

N/A

N/A

N/A

170 (86.7)

51 (81.0)

20 (69.0)

22 (100.0)

2 (66.7)

 MSI

29 (11.3)

26 (15.1)

9 (100.0)

13 (20.0)

0 (0.0)

N/A

N/A

N/A

N/A

N/A

26 (13.3)

12 (19.0)

9 (31.0)

0 (0.0)

1 (33.3)

 Missing

12

14

1

6

1

2